KYTX
NASDAQKyverna Therapeutics Inc.
$5.68+0.04 (+0.62%)
Kyverna Therapeutics Inc. (KYTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for KYTX, including 4 press releases and news items. The most recent was published Oct 23, 2026.
Price$5.68-0.01 (-0.27%)
01:30 PM02:00 PM
News · 26 weeks34+100%
2026-05-032026-10-25
Mix1190d
- Other7(64%)
- SEC Filings3(27%)
- Earnings1(9%)
Latest news
25 items- PRKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies Durable results extending beyond two years in the first patient treated Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027 EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a lat
- PRKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoMiv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel's unique construct Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up Data further strengthens SPS BLA package and supports potential for miv-cel to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune diseases EMERYVILLE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics,
- SECSEC Form SCHEDULE 13G filed by Kyverna Therapeutics Inc.SCHEDULE 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- PRKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for present
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia GravisTopline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026 Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE; Phase 3 enrollment expected to be completed in mid-2027 Consistent, well-tolerated safety pro
- PRKyverna Therapeutics to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences: 2026 Wells Fargo Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Wednesday, September 9th, 2026Time: 4:30 p.m. ET Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Monday, September 14th, 2026Time: 4:05 p.m. ET H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside chat and investor mee
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsFDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026 Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026 Reiterates operating runway into 2028 EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential launches in stiff person syndrome (SPS) and general
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage TransitionEMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization. "Ritesh is a key addition to Kyverna as we prepare fo
- PRKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisMajority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date1 Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases,
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- INSIDERDirector Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Seidenberg Beth C was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERExecutive Chairperson Shaw Christi covered exercise/tax liability with 4,194 shares, decreasing direct ownership by 6% to 66,741 units (SEC Form 4) to cover taxes4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Aktar Mert was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 3 filed by new insider Martini Gregory S.3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Martini Gregory S.4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
KYTX FAQ
7 questionsWhat is the latest news on KYTX?
In the last 30 days Quantisnow tracked 4 wire items for KYTX: 4 press releases and news items. The most recent was published on October 23, 2026.Where does KYTX stock trade?
Kyverna Therapeutics Inc. (KYTX) is listed on NASDAQ.What sector and industry is KYTX in?
Kyverna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kyverna Therapeutics Inc. go public?
Kyverna Therapeutics Inc. (KYTX) completed its IPO in 2024.What are analysts saying about KYTX?
Kyverna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2025-08-20.What companies are similar to KYTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KYTX side-by-side with any of them on Quantisnow.How can I track KYTX on Quantisnow?
Quantisnow aggregates Kyverna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYTX to receive live email and push alerts on every new disclosure.